Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

36 37 Next >

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond ↗

December 17, 2023

Many investors are bailing out, but that might be a mistake.

Via The Motley Fool

The Latest Analyst Ratings for Sarepta Therapeutics ↗

December 12, 2023

Via Benzinga

Could Sarepta Therapeutics Stock Help You Become a Millionaire? ↗

December 09, 2023

Can this struggling stock turn its fortunes around?

Via The Motley Fool

My Take: 4 Strong Growth Stocks to Buy This Week ↗

December 08, 2023

These strong stocks are still available at a great price. That may not be the case a whole lot longer.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Analyst Ratings for Sarepta Therapeutics ↗

November 21, 2023

Via Benzinga

1 Gene Therapy Stock to Buy and Hold for the Long Haul ↗

November 08, 2023

The biotech has what it takes to overcome recent obstacles.

Via The Motley Fool

Analyst Ratings for Sarepta Therapeutics ↗

November 02, 2023

Via Benzinga

Why Sarepta Therapeutics Stock Is Crashing Today ↗

October 31, 2023

There's a plot twist with Sarepta's disappointing clinical results.

Via The Motley Fool

ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

November 18, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Via The Motley Fool

3 Stocks You’ll Regret Not Buying Soon: November 2023 ↗

November 16, 2023

These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.

Via InvestorPlace

SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

November 15, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy ↗

November 15, 2023

Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the

Via Benzinga

Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There' ↗

November 15, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.

Via Benzinga

Topics Artificial Intelligence

Is Sarepta Therapeutics Stock a Bad-News Buy? ↗

November 09, 2023

Analysts still expect some sizable returns from the stock.

Via The Motley Fool

Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks? ↗

November 08, 2023

Just because a stock is "on sale" doesn't inherently make it worth purchasing.

Via The Motley Fool

SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

November 07, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

8 Health Care Stocks Whale Activity In Today's Session ↗

November 07, 2023

Via Benzinga

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Sarepta Therapeutics to Present at the UBS Biopharma Conference

November 02, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

SRPT earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

November 01, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

What's Going On With Biotech Contract Service Firm Catalent Stock Today? ↗

October 31, 2023

Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.

Via Benzinga

Earnings Scheduled For November 1, 2023 ↗

November 01, 2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Via Benzinga

Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss ↗

October 31, 2023

Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to

Via Benzinga

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 31, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 31, 2023

Via Benzinga

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

October 31, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.